New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

BACKGROUND: With the exception of the FDA-approved valrubicin and pembrolizumab, there are no standard second-line treaments for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). OBJECTIVES: To provide a systematic review of the novel intravesically administered therapeutic agen...

Full description

Bibliographic Details

Published in:	Bladder Cancer
Main Authors:	Anastasios D. Asimakopoulos, Maxim Kochergin, Gaia Colalillo, Omar Fahmy, Fahmy Hassan, Markus Renninger, Andrea Gallioli, Pavel Gavrilov, Georgios Gakis
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-09-01
Online Access:	https://doi.org/10.3233/BLC-230043